99 results about "Anticancer treatment" patented technology

The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring therapy can be used for prognostic (predictive) purposes to thereby treat an individual having cancer. Accordingly, one aspect of the present invention relates to methods of treating a subject having cancer by determining the amount and / or activity level of ZNFX1 in the context of a biological sample (e.g., blood, serum, cells, or tissue) to thereby determine whether an individual afflicted with a cancer is likely to respond to anti-cancer therapy, whether in an original or recurrent cancer.

The utility model discloses engineering bacteria photo-thermal hydrogel smearing equipment which comprises a fixing frame, a smearing mechanism, a transmission mechanism and a uniform smearing part, the transmission mechanism is arranged on the fixing frame and can drive base layer cloth to transmit, the smearing mechanism can coat hydrogel and attach the hydrogel to the base layer cloth, and the uniform smearing part is located on one side of the smearing mechanism. The smearing mechanism can evenly smear hydrogel smeared on base layer cloth, the even smearing component comprises an even smearing plate and a lifting component, a gap exists between the even smearing plate and the conveying mechanism, and the lifting component can adjust the size of the gap between the even smearing plate and the conveying mechanism. The prepared hydrogel can be attached to the position needing to be treated, for example, the hydrogel can be applied to the fields of skin wounds and anti-cancer treatment.

The present invention relates to a modified mitochondrial comprising, on the outer membrane of the mitochondrial, an antibody that binds to a cancer cell-specific protein and a cytosine deaminase. It is proved that when the mitochondria and 5-FC are jointly used for treating a pancreatic cancer cell line, the cytotoxicity induced by 5-FC treatment is remarkably enhanced. The effect is proved as follows: 5-FC is converted into 5-FU by cytosine deaminase expressed on a mitochondrial outer membrane, so that pancreatic cancer cells are induced to generate apoptosis. Therefore, the modified mitochondria according to the present invention can be effectively used in anticancer therapy using 5-FC as an anticancer agent.

The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.

A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of an inhibitor of nuclear import protein Karyopherin Beta 1 (Kpnβ1) such as the substituted pyrrolo[2,3-b]quinoxalines of Formula I and a therapeutically effective amount of an inhibitor of nuclear export protein Chromosome Maintenance 1 (Crm1) such as the hydrazide- containing compounds of Formula II. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of each of the nuclear transport inhibitors administered alone.

The application provides an active oxygen response type artificial ion channel, and a structural general formula is as follows: the application is activated by high level ROS in cancer cells, the activated channel promotes the synergistic transmembrane transmission of H + and Cl ‑ ions, thereby realizing specific anticancer treatment, the synthetic route of the application is green, simple, efficient, raw materials are easy to obtain, and can be used for synthesis of similar compounds.

Disclosed herein are methods for treating cancer with inhibitors of FN14 (e.g., Compound 1), or pharmaceutically acceptable salts thereof. The disclosure further provides methods of treating cancer with inhibitors of FN14 or pharmaceutically acceptable salts thereof, in combination with additional anti-cancer therapeutics (e.g., a kinase inhibitor).

The invention provides a chelating agent for use in a method of treating cancer in a subject, wherein said cancer has a resistance to an anti-cancer therapeutic agent. Further, the invention provides a chelating agent for use in a method of sensitizing a subject for an anti-cancer treatment and / or counteracting a resistance to an anti-cancer therapeutic agent, wherein the method restores or re-activates a tumor suppressor protein function that preferably was impaired due to aberrant tumor suppressor protein folding. The invention also provides a pharmaceutical composition comprising a 2,3-Dimercapto-1-propanesulfonic acid (DMPS) or DMSA, preferably miaDMSA, and a pharmaceutically acceptable excipient; wherein the DMPS is present in a dose of 40-12000 mg.

The invention belongs to the field of organic photoelectric materials, and particularly discloses a near-infrared two-region (NIR-II) multi-resonance hybrid four-free-radical molecule and preparation and application thereof, the structure of the molecule is as follows: in addition, the research on free radical materials in the aspect of NIR-II fluorescence imaging guided photo-thermal anticancer treatment is still limited, and the molecule has a wide application prospect. And the material is mainly concentrated on a double-free-radical material. A chain D-A-A-D type organic four-free-radical compound is designed and synthesized on the basis of a classical Cichibabin skeleton, the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound is high in stability and has the near-infrared two-region photoluminescence property, the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound is applied to research in biological photo-thermal anticancer treatment, and the near-infrared two-region light-emitting multiple resonance hybrid four-free-radical molecular compound has a wide application prospect. And the photo-thermal conversion efficiency of 87% is shown.

Mixing a low-viscosity solution and a high-viscosity solution was difficult. An object of the present invention is to provide a holder for mixed administration of at least two types of solutions for enhancing the radiation or anticancer therapeutic effect on a tumor, wherein the holder is capable of simultaneously discharging each solution at a constant ratio from respective syringes containing each solution.

A tumor-targeting protein or a fragment thereof, an antibody binding thereto and a use thereof are disclosed. A vector containing a nucleic acid coding for protein A56 or a fragment thereof, and a use thereof are disclosed. An antibody binding to protein A56 or a fragment thereof, and a use thereof are disclosed. The vector containing A56-encoding nucleic acid, a fragment thereof or a mutant thereof uses an oncolytic virus as the vector, and thus, when administered in an individual, specifically kills only cancer cells, primarily. In addition, cancer cells which have survived even after being infected with the oncolytic virus express the protein A56 on the cell surfaces thereof, and thus may be targeted for secondary anticancer therapy employing protein A56-encoding nucleic acid or protein A56 or a fragment thereof, or an antibody binding to A56.

Disclosed herein are programmable bacteria for tumor-targeted immunotherapeutic delivery. In certain embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents including but not limited to nanobodies against immune checkpoint inhibitors and over-expressed markers in cancers, toxins, tumor antigens, cytokines, and chemokines. In some embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon and at least one plasmid producing a therapeutic agent, i.e., at least one plasmid comprising a nucleic acid sequence which encodes a therapeutic agent. The disclosure also provides methods of curing and treating cancer using the programmable bacteria.

The present invention relates to treatment of a cancer of the central nervous system, in particular the use of Wallerian degeneration inhibitors in the treatment of CNS cancer. Also provided are in vivo and in vitro methods of screening Wallerian degeneration inhibitors as anti-CNS cancer therapeutic compounds.

The present invention relates to a composition for the prevention or treatment of metastatic cancer, capable of inducing an abscopal effect, which is a systemic anticancer effect, in combination with radiotherapy to treat metastatic cancer that has spread from a primary cancer, wherein, by having confirmed that, upon radiotherapy in which a primary cancer site was irradiated with a low dose of radiation, the abscopal effect, which is a systemic anticancer effect, did not appear, whereas, when type 1 interferon was administered in combination with low-dose radiation to the primary cancer site, an anticancer effect appears even in non-radiated metastatic cancer sites, a composition comprising type 1 interferon is provided as a therapeutic agent or adjuvant for the treatment of metastatic cancer, which induces a systemic anticancer effect upon low-dose radiotherapy.

The present disclosure provides methods and compositions for treating cancer (e.g., lung cancer) in a subject by increasing the expression of PDZ-LIM domain containing protein 2 (PDLIM2) in the subject, or a functional fragment thereof. The present disclosure further provides methods of using PDLIM2 as a marker for determining and monitoring a subject's responsiveness to an anti-cancer treatment, providing a prognosis about a cancer in a subject, and selecting an effective anti-cancer treatment for a subject. The present disclosure also provides in vitro methods of screening anti-cancer agents by assessing whether the expression of PDLIM2 is restored by an anti-cancer agent in a cancer cell.

The invention belongs to the technical field of biological medicines, and particularly relates to a furo-quinoline dictamnine derivative as well as a preparation method and application thereof. The compound is novel and stable in structure, has a remarkable anti-cancer effect, particularly has a relatively high inhibition rate on NCI-H460 and 786-O tumor cells, has relatively low IC50, has a remarkable anti-tumor cell effect, and has a relatively good application prospect in the aspect of anti-cancer treatment. Besides, the preparation method of the furo-quinoline dictamnine derivative has the advantages of wide substrate application range, good functional group compatibility, mild reaction conditions, simplicity and convenience in operation and the like, can be used for large-scale industrial production, and has wide application value in the aspect of developing anti-cancer drugs.

The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.

The description discloses selective and potent CDK 4 / 6 inhibitors that exhibit advantageous inhibition of cancer growth, even at low concentrations. One class of CDK 4 / 6 inhibitors refers to substituted pyrrolopyrimidine compounds having a fatty acid moiety and specifically derived from Palbociclib of the general formula [2A], where R1 is hydrogen, aryl, alkyl, alkoxy, cycloalkyl, or heterocyclyl; R2 is hydrogen, halogen, alkyl, acyl, cycloalkyl, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, nitrile, or nitro; R3 is hydrogen, halogen, alkyl, haloalkyl, hydroxyalkyl, or cycloalkyl; yn is an integer from 9 to 20. These compounds can be used as pharmaceutical compounds for anticancer therapies and are useful for the treatment, prevention and / or improvement of cancer.

The present invention relates to a composition comprising a TAF10 inhibitor for preventing or treating colorectal cancer. The inhibition of TAF10 was found to lead to suppressing the growth and proliferation of colorectal cancer cells, reducing vascularization, and inhibiting the WNT signaling pathway, and increase the survival rate of patients as analyzed with a large-scale cancer database. In particular, reversal of the cancerization process, which is the differentiation of colorectal cancer cells into normal cells, was confirmed. Unlike conventional anticancer agents that simply induce the death of cancer cells, the present invention can thus be advantageously utilized as a treatment method for converting colorectal cancer cells into normal cells while excluding side effects of normal cell death that may occur during anticancer treatment.

The present invention relates to a method of assessing or monitoring the response of a patient suffering from cancer after receiving an anti-cancer treatment, said method being based on the detection of biomarkers. The invention also relates to a kit for carrying out said method and to a method for treating said patient.

The invention relates to two kinds of siRNA (small interfering Ribonucleic Acid) targeting heterogeneous ribonucleoprotein C, wherein the siRNA comprises si-Hnrnpc-1 and si-Hnrnpc-2. Compared with the prior art, the siRNA disclosed by the invention has the advantages that the mRNA accessibility, space occupying factors and gene functional regions are considered, the probability of miss of family and cross-family miss can be reduced, Hnrnpc expression can be effectively reduced, meanwhile, the siRNA has clear targeting and biological effects, and the siRNA has important research value and application prospect for future cancer mechanisms and anti-cancer treatment.

An anticancer agent is provided comprising, as active ingredients, NK cells and a fusion protein comprising an IL-2 protein and a CD80 protein. In one specific formulation, a fusion protein comprising a CD80 fragment, an immunoglobulin Fc region, and an IL-2 variant can activate immune cells such as natural killer cells. Furthermore, since the pharmaceutical composition can effectively inhibit cancer, when co-administered with natural killer cells, it increases immune activity in the body, making it effective for cancer treatment and thus highly applicable to industry.

To provide novel therapeutic compounds that target and inhibit a mitochondrial function, and may serve as anti-cancer therapeutics.SOLUTION: Alkyl-triphenylphosphonium compounds having a saturated, linear alkyl chain of about 9 to about 18 carbons may be used as therapeutic agents to treat cancer. Demonstrative compound dodecyl-TPP (d-TPP) dose-dependently inhibits the propagation of breast cancer stem cells and targets the bulk of the adherent of cancer cells, by decreasing MCF-7 cell viability. Further, d-TPP potently inhibits a mitochondrial oxygen consumption rate, while simultaneously shifting cell metabolism toward a glycolytic pathway. This shift to a strict metabolic dependency on glycolysis may be used to eradicate the residual glycolytic CSC population, by using additional metabolic stressors. For example, d-TPP may be combined with a glycolytic inhibitor or an OXPHOS inhibitor, through co-administration or sequential administration, to treat cancer and eradicate CSCs.SELECTED DRAWING: Figure 2

The present invention relates to a bispecific antibody fragment in which a nanobody specifically binding to EpCAM is connected by a flexible peptide linker ((GGGGS)n) to a single-chain antibody fragment (scFv) specifically binding to CD3, and is an antibody platform technology for anticancer therapy, wherein a selective point mutation is introduced into the antigen-binding site (CDR) of the antibody, thereby modulating binding affinity for an antigen and immunological safety. The design is such that the EpCAM-binding domain has maximized accessibility and selective binding ability to solid cancer cells by having utilized a nanobody having excellent tissue penetration, and the CD3-binding domain can inhibit T-cell overactivation and immunotoxicity (CRS) by having utilized scFv, the affinity of which can be modulated based on the therapeutic purpose. In particular, the affinity of antibody fragments to EpCAM and CD3 antigens is stably maintained or improved even under weakly acidic conditions (pH 5.6 to 6.7) of the tumor microenvironment, indicating that the antibody fragments can exhibit excellent anticancer effects even in solid cancer environments.

The present invention relates to a method for developing personalized targeted anticancer therapy based on aptamers and systemically modeling individuals in a microfluidic device. In one embodiment, the present invention provides a method for developing targeted therapy comprising maintaining targeted cancer cells in co-culture with non-target non-cancer cells using a microfluidic device modularly arranged within a closed system to develop aptamers. In another embodiment, the present invention provides a method for developing targeted therapy comprising maintaining target cells in co-culture with non-target cells using a microfluidic device modularly arranged in a closed system. In this regard, the present invention provides development of aptamers for relevant targets that are in homeostatic balance with fluidic components modulated by co-culture with non-target cells.

The invention provides an indole compound as well as a preparation method and application thereof. The structural formula of the compound is shown as a formula (I), a formula (II) or a formula (III). The compound provided by the invention is used as an ATP (adenosine triphosphate) competitive sphingosine kinase 1 (SphK1) or 2 (SphK2) inhibitor, and shows strong enzyme inhibition activity and an effect of resisting tumor cell proliferation. Experiments prove that the indole compound provided by the invention has the potential to be developed into an anti-tumor therapeutic drug and an anti-pulmonary arterial hypertension therapeutic drug, and a new direction is provided for the field of anti-cancer therapeutic drugs. The preparation method of the compound is simple, low in cost, free of dangerous reagents and suitable for industrial production.

The present disclosure provides CDK2 inhibitor compounds that can have a fused 6-6 bicyclic core, such as a naphthyridine, quinazoline, pyridopyrimidine or related isosteric core structure that is further substituted. Also provided herein are pharmaceutical compositions including the subject CDK2 inhibitor compounds, and methods for using compositions of the disclosure as anticancer therapeutics.

This invention provides a compound having the following structure: ( I ) wherein the compound is used for anti-cancer treatments. The invention also provides an assay for selecting one or more compounds that inhibit interaction between ID2 protein and the tumor suppressor complex CRLVHL.